Physician profile
Syed Waliuddin
NPI 1104046630
$32,135.91
in general payments reported to CMS, 2019-2025
19 companies · $46.91 in 2025
The $46.91 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,623 · 2021: $5,179 · 2022: $5,206 · 2023: $5,529 · 2024: $155 · 2025: $46.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,225 · Travel and Lodging: $872 · Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,225.00 |
| Travel and Lodging | $872.05 |
| Food and Beverage | $634.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14,212.46 | 2019-2020 | |
| Abbvie INC. | $13,185.79 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $2,564.06 | 2021-2023 | Qelbree |
| Neos Therapeutics, LP | $724.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $413.52 | 2019-2021 | |
| Tris Pharma INC | $272.79 | 2019-2024 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $239.22 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $123.73 | 2019-2020 | |
| Lundbeck LLC | $115.41 | 2019-2021 | |
| Shire North American Group INC | $50.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.37 | 2019 | |
| Vertical Pharmaceuticals, LLC | $33.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.83 | 2019 | |
| Bausch Health US, LLC | $30.13 | 2019 | |
| Alkermes, INC. | $29.23 | 2023 | Aristada, Lybalvi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.34 | 2022 | |
| Indivior INC. | $15.92 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.72 | 2025 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Waliuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.